FDA warns about false positive results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP kits

Sept. 21, 2021

The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and healthcare providers of the potential for false positive results with the Alinity m SARS-CoV-2 AMP Kit, List Number 09N78-095, and Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096.

The false positive results may be related to current mixing parameters of the PCR reaction mixture that may result in potential overflow that could carry over into neighboring wells in the assay reagent tray. Overflow into the wells of true negative samples that are positioned near positive samples in the assay tray could produce false positive results.

The FDA recommends that clinical laboratory staff and healthcare providers:

Consider any positive result from tests using the Alinity m SARS-CoV-2 AMP and the Alinity m Resp-4-Plex AMP Kits to be presumptive. Consider retesting positive patient specimens performed in the last two weeks with an alternate authorized test.

Consider communicating to patients who received positive results using the Alinity m SARS-CoV-2 AMP and the Alinity m Resp-4-Plex AMP Kits, starting in June 2021, that they may have had a false positive test result.

The FDA issued an Emergency Use Authorization (EUA) to permit emergency use of the Alinity m SARS-CoV-2 AMP test on May 11, 2020 and granted revisions to the EUA with the most recent revision granted in August 2021. The Alinity m SARS-CoV-2 AMP Kit is only authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform moderate or high complexity tests.

The FDA issued an Emergency Use Authorization (EUA) to permit emergency use of the Alinity m Resp-4-Plex AMP test on March 4, 2021. The Alinity m Resp-4-Plex AMP Kit is only authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform moderate or high complexity tests.

FDA Actions

The FDA is working with Abbott Molecular Inc. to resolve these issues. The FDA will continue to keep clinical laboratory staff, health care providers, and the public informed of significant new information.

FDA warning letter

More on COVID

Illustration 95879673 © Sandamali Fernando | Dreamstime.com
Photo 202771086 © Kapil Joshi | Dreamstime.com
Photo 159538255 © Thanee Hengpattanapong | Dreamstime.com
Photo 144935703 © Andrey Metelev | Dreamstime.com